Unjha Formulations Limited is a specialized Indian pharmaceutical and Ayurvedic manufacturer with a dominant focus on **Isabgol (Psyllium) husk-based formulations** and veterinary products. The company operates a dual-revenue model: developing its proprietary brands while serving as a strategic **third-party contract manufacturer** for global and domestic pharmaceutical giants. Strategically headquartered in **Gujarat**, the company is currently undergoing a multi-dimensional transformation—expanding into high-growth skincare markets through its **Alvio Pharmaceuticals** division, scaling its international export footprint, and aligning with India’s emerging **Free Trade Agreements (FTAs)** and **ESG (Environmental, Social, and Governance)** frameworks. --- ### **Core Manufacturing Segments & Strategic Partnerships** The company’s operational core is divided into two primary specialized divisions, supported by a robust network of multinational partners. #### **1. Ayurvedic & Pharmaceutical Divisions** * **Ayurvedic Division:** Focuses on traditional wellness integrated with modern delivery. Key brands include **Sat-Isabgol** and the **LAXOVEL Group** (flavored formulations). * **Pharmaceutical & Veterinary Division:** Produces specialized treatments including **Albendazole Bolus** for the veterinary market, and digestive health products like **Fibron-SF Orange Powder** and **Fibermate**. #### **2. Strategic Contract Manufacturing Portfolio** Unjha Formulations acts as a critical supply chain partner for several industry leaders through loan license arrangements: | Partner Entity | Product / Brand Focus | | :--- | :--- | | **Reckitt Benckiser India Ltd** | Fybogel | | **Abbott Healthcare Pvt Ltd** | FABOLITE | | **Karnataka Antibiotics & Pharmaceuticals Ltd** | Husky / Isabgol Husk products | | **Apollo Pharmacy** | Sat-Isabgol (Private Label) | | **Radiant Nutraceutical (Bangladesh)** | Export-based manufacturing | | **Nutragenix Healthcare Pvt Ltd** | Fibapure Group | | **Rhine Biogenics Pvt Ltd** | Specialized Formulations | --- ### **New Growth Engine: Alvio Pharmaceuticals & Uncap Skincare** In **May 2025**, the company diversified into the high-margin beauty and wellness sector via **Alvio Pharmaceuticals**. This division targets the "clean beauty" trend with its flagship brand, **Uncap**. * **Product Range:** A launch portfolio of **17 products** that are fragrance-free, dermatologically tested, and non-greasy. * **Holistic Approach:** Unlike traditional topical-only brands, Uncap combines external treatments with **Hydro Supplements** (effervescent tablets and powders) to address skin health at a cellular level. * **Target Segments:** * **Brightening & Whitening:** Pigmentation and tone correction. * **Anti-Aging ("Rewind"):** Age-related skin changes. * **Anti-Acne ("Smooth"):** Early-stage breakouts and clarity. * **Barrier Repair:** Intensive moisturizing and hydration. --- ### **Global Trade Strategy & Export Performance** The company is aggressively pivoting toward international markets to offset domestic demand fluctuations and capitalize on India’s expanding trade network. * **Export Footprint:** Key international products include **Albendazole Bolus** and Isabgol formulations. The company recently secured a manufacturing contract with a major **South American pharmaceutical firm**. * **India-EU FTA Integration:** The company is positioning itself to benefit from the **India-EU Free Trade Agreement**, which provides **99% duty-free access** to EU markets. This is expected to lower tariffs (previously **10%**) to **zero** for engineering and chemical-related goods. * **Professional Mobility:** Leveraging the **Intra-Corporate Transferee (ICT)** framework to facilitate the movement of R&D and technical staff across global borders. **Export Value Trends:** | Financial Year | Export Value (INR) | Export Value (USD) | | :--- | :--- | :--- | | **2023-24** | **~3.90 Crore** | **~4,70,788** | | **2022-23** | **~5.84 Crore** | **~8,06,096** | --- ### **Financial Profile & Capital Structure** Unjha Formulations maintains a **debt-free** status, though it is currently focused on clearing historical accumulated losses to strengthen its equity base. **Financial Summary (As of March 31, 2023):** | Particulars | Value (Rs. in Lakhs) | | :--- | :--- | | **Total Revenue** | **1,285.48** | | **Profit Before Tax (PBT)** | **28.25** | | **Earnings Per Share (EPS)** | **0.63** | | **Paid-up Equity Capital** | **448.05** | | **Other Equity (Reserves & Surplus)** | **(202.71)** | | **Total Assets** | **340.99** | | **Long-term Borrowings** | **NIL** | * **Liquidity:** Current assets of **Rs. 231.48 Lakhs** are primarily tied to **Inventories (Rs. 113.65 Lakhs)** and **Trade Receivables (Rs. 104.88 Lakhs)**. * **Asset Base:** Includes **Property, Plant and Equipment (PPE)** valued at **Rs. 56.98 Lakhs** and **Intangible Assets** of **Rs. 50.00 Lakhs**. --- ### **Operational Infrastructure & ESG Integration** * **Manufacturing Excellence:** The plant is located on the **State Highway, Sidhpur, Gujarat**, utilizing technology-driven methods to ensure quality is "built-in" rather than just inspected. * **The SATVA Initiative:** Launched in **July 2025**, this long-term sustainability program integrates **ESG principles** into daily operations, focusing on ethical sourcing and environmental stewardship. * **Internal Controls:** Continuous review processes ensure compliance with the **Companies Act, 2013**, and operational efficiency. --- ### **Strategic Macro-Alignment & Future Outlook** The company is aligning its long-term growth with India’s **Vision 2047** and major industrial shifts: * **Infrastructure & Materials:** Through interests in sustainable building (e.g., **BigBloc Construction**), the company is tapping into the **AAC Blocks and Panels** market, which saw revenue growth of **30.3% YoY** in Q2FY26. * **Energy & Tech Transition:** Monitoring opportunities in the **$100 billion** Oil & Gas investment space and the **Dholera SIR** semiconductor ecosystem. * **Regulatory Adaptation:** Navigating the **Mines and Minerals Amendment Bill 2023** and the **Carbon Border Adjustment Mechanism (CBAM)** to ensure supply chain security for critical minerals and "green" compliance for European exports. --- ### **Risk Factors & Mitigation** * **Non-Tariff Barriers:** Navigating **Sanitary and Phytosanitary (SPS)** measures and **Technical Barriers to Trade (TBT)** in the EU and South American markets. * **Market Volatility:** Addressing the **SEBI** norms regarding **Open Interest (OI)** and index option limits designed to curb retail speculation. * **Resource Security:** Managing the transition from import-dependence to domestic sourcing for critical minerals required in high-tech pharmaceutical manufacturing equipment. * **Accumulated Losses:** The primary financial risk remains the **Rs. 202.71 Lakhs** in negative reserves, which the company aims to offset through its new high-margin skincare and export initiatives.